Compare The Coca-Cola Co K (KO) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Zimmer Biomet Holdings Inc — how do they compare? The Coca-Cola Co K trades at $81.9 (market cap $353.32B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: The Coca-Cola Co K is far larger — about 20.4× Zimmer Biomet Holdings Inc's market cap, and The Coca-Cola Co K pays the higher dividend (2.58%). Which is the better fit depends on your goals.
| KO | ZBH | |
|---|---|---|
Market Cap | $353.32B | $17.36B |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Health |
52-Week High | $84.92 | $107.71 |
52-Week Low | $65.67 | $79.58 |
Enterprise Value | $383.39B | $24.40B |
Dividend Yield | 2.58% | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $81.56, down 3.96% on the day, with a bearish technical signal but strong fundamentals including a 27.8% net income margin and consistent earnings beats. Recent news highlights institutional accumulation and steady dividend payments. The stock is supported by robust cash flow and brand strength, though near-term price action shows weakness below key resistance.
Outlook remains positive with a consensus price target of $90.67, offering ~11% upside. Risks include regional demand divergence and high debt levels. The stock presents a value opportunity for dividend-focused investors given its 64-year dividend growth streak, but macroeconomic pressures warrant caution.
Zimmer Biomet (ZBH) trades at $89.74, down 1.51% on the day, with a bullish technical signal from moving averages and a consensus price target of $97.67. The company reported revenue of $8.23B in 2025, with net income of $705.10M and a net margin of 8.56%. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase program, while Q2 2026 earnings are anticipated on August 5, 2026.
ZBH presents a mixed outlook with strong profitability margins and recent earnings beats offset by declining net income margins and rising debt levels. The stock offers potential upside to analyst targets but faces execution risks in competitive medical markets and macroeconomic pressures on healthcare spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
